Advertisement
Canada markets closed

  • S&P/TSX

    22,465.37
    +165.57 (+0.74%)
     

  • S&P 500

    5,303.27
    +6.17 (+0.12%)
     

  • DOW

    40,003.59
    +134.19 (+0.34%)
     

  • CAD/USD

    0.7349
    +0.0001 (+0.01%)
     

  • CRUDE OIL

    80.00
    -0.06 (-0.07%)
     

  • Bitcoin CAD

    90,757.73
    -751.77 (-0.82%)
     

  • CMC Crypto 200

    1,360.43
    -13.41 (-0.98%)
     

  • GOLD FUTURES

    2,437.60
    +20.20 (+0.84%)
     

  • RUSSELL 2000

    2,095.72
    -0.53 (-0.03%)
     

  • 10-Yr Bond

    4.4200
    +0.0430 (+0.98%)
     

  • NASDAQ futures

    18,674.50
    +39.25 (+0.21%)
     

  • VOLATILITY

    11.99
    -0.43 (-3.46%)
     

  • FTSE

    8,420.26
    -18.39 (-0.22%)
     

  • NIKKEI 225

    39,346.92
    +559.54 (+1.44%)
     

  • CAD/EUR

    0.6754
    -0.0001 (-0.01%)
     

2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024

Business Wire
·2 min read

CAMBRIDGE, Mass., May 03, 2024--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. A conference call and webcast will be held at 8:00 a.m. ET.

Participants can access the conference call live via webcast which will be available on the Investors and Media page of the company’s website at https://ir.2seventybio.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. It is recommended that participants join 10 minutes prior to the event’s start. A replay of the call will be available on the 2seventy bio website following the completion of the call.

About 2seventy bio

Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to give the people we serve more time. With a deep understanding of the human body’s immune response to tumor cells and how to translate cell therapies into practice, we’re applying this knowledge to deliver the first FDA-approved CAR T cell therapy for multiple myeloma to as many patients as possible. Importantly, we remain focused on accomplishing our mission by staying genuine and authentic to our "why" and keeping our people and culture top of mind every day.

ADVERTISEMENT

For more information, visit www.2seventybio.com.

Follow 2seventy bio on social media: X (Twitter) and LinkedIn.

2seventy bio is a trademark of 2seventy bio, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240503081790/en/

Contacts

Investors:
Vicki Eatwell, CFO
vicki.eatwell@2seventybio.com

Jenn Snyder
Jenn.snyder@2seventybio.com

Media:
Jenn Snyder
Jenn.snyder@2seventybio.com